Gastro Esophageal Junction Neuroendocrine Tumor Gej Net Market Size
DelveInsight's Gastro-Esophageal Junction Neuroendocrine Tumor (GEJ-NET) - Market Insights, Epidemiology, and Market Forecast-2028-United States report delivers an in-depth understanding of the disease, historical and forecasted epidemiology as well as the market trends of Gastro-Esophageal Junction Neuroendocrine Tumor (NET) in the United States.
The Report provides the current treatment practices, emerging drugs, market share of the individual therapies, the current and forecasted market size of Gastro-Esophageal Junction Neuroendocrine Tumor (GEJ-NET) from 2017 to 2028 in the United States market. The Report also covers current treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assess the underlying potential of the market.
• The United States
Study Period: 2017-2028
Gastro-Esophageal Junction Neuroendocrine Tumor (GEJ-NET) - Disease Understanding and Treatment Algorithm
The GEJ-NET is defined as the poorly differentiated area where the distal (lower) esophagus-NET joins the proximal stomach (cardia)-NET. The gastro-esophageal junction is notable because of the epithelial transition that takes place there. At this point, there is a shift from the stratified squamous epithelium of the esophagus to the simple columnar epithelium of the stomach.
DelveInsight's GEJ-NET market report gives a thorough understanding of the GEJ-NET by including details such as disease definition, classification, symptoms, etiology, pathophysiology, diagnostic trends. It also provides treatment algorithms and treatment guidelines for GEJ-NET in the US.
Gastro-Esophageal Junction Neuroendocrine Tumor (GEJ-NET) - Epidemiology
The Gastro-Esophageal Junction Neuroendocrine Tumor (GEJ-NET) epidemiology division provide insights about historical and current patient pool and forecasted trend for the United States. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight's report also provides the diagnosed patient pool and their trends along with assumptions undertaken.
The disease epidemiology covered in the report provides historical as well as forecasted epidemiology [segmented by Total Diagnosed Prevalent Population, and Grade -Specific Diagnosed Prevalent Population] scenario of Gastro-Esophageal Junction Neuroendocrine Tumor (GEJ-NET) in the United States from 2017-2028.
As per DelveInsight's estimates, the Gastroenteropancreatic NET (GEP-NET) accounts for ~61% of all NET cases. We have also observed that the frequency of esophagus and stomach was accounted 0.24% (0.39% of GEP-NETs) and 6.02% (9.79% of GEP-NETs), respectively of all NET cases. Of all Esophagus NET, upper-middle esophagus NET comprised of a significantly lesser proportion of the patients, as compared to lower esophagus NET, whereas of all Gastric NET cases, gastric cardia NETs account for approximately 11% and gastric non cardia NET accounts for ~89% cases.
DelveInsight's estimations suggest that the total diagnosed prevalent population of GEJ-NET in the United States was assessed to be 588 in 2017. The diagnosed prevalent cases in the United States is expected to increase with the CAGR of XX% for the study period of 2017-2028.
Furthermore, our estimations suggests that in the Grade-Specific segmentation of GEJ-NET, majority of the cases were observed for Grade 3 (poorly differentiated and undifferentiated or anaplastic), followed by the number of cases for Grade 1 (well differentiated), while Grade 2 (moderately differentiated) accounted for least percentage of patient pool.
Gastro-Esophageal Junction Neuroendocrine Tumor (GEJ-NET) - Drug Chapters
This segment of the Gastro-Esophageal Junction Neuroendocrine Tumor (NET) report encloses the detailed analysis of marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.
Lutathera is a radio-labeled somatostatin analog indicated for the treatment of somatostatin receptor-positive Gastroenteropancreatic Neuroendocrine Tumors (GEP-NET) including foregut, midgut, and hindgut neuroendocrine tumors in adults. The drug is administered intravenously. Lutetium Lu 177 dotatate binds to somatostatin receptors with the highest affinity for subtype 2 receptors (SSRT2). Upon binding to somatostatin receptor expressing cells, including malignant somatostatin receptor-positive tumors, the compound is internalized. The beta emission from Lu 177 induces cellular damage by the formation of free radicals in somatostatin receptor-positive cells and in neighboring cells. The drug belongs to the peptide receptor radionuclide therapy (PRRT) class, which carries a radioactive component for treatment.
Gastro-Esophageal Junction Neuroendocrine Tumor (GEJ-NET) - Market Outlook
The Gastro-Esophageal Junction Neuroendocrine Tumor (NET) market outlook of the report helps to build the detailed comprehension of the historic, current and forecasted trend of the market by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.
This segment gives a thorough detail of market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria's, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.
Gastroesophageal Junction Neuroendocrine Tumor (GEJ-NET) involves cases of lower esophageal and gastric cardia neuroendocrine tumors. The treatment options include surgery (esophagectomy), chemotherapy, radiotherapy, and endoscopic treatment.
In addition, the current treatment options for Gastroesophageal Junction Neuroendocrine Tumor includes off-label products (chemotherapy and cytotoxic agents) and targeted therapies that are being used for the treatment of GEJ-NETs are contributing towards the market revenue of GEJ-NETs. Cytotoxic therapies such as 5-FU, or temozolomide are considered in the palliation of patients with advanced GEJ-NET and symptoms related to tumor bulk. Furthermore, surgical treatment is the main method used to cure the disease.
The market size of Gastro-Esophageal Junction Neuroendocrine Tumor (NET) in the United States is USD 24.98 Million in 2017, which is expected to increase at a CAGR of XX % for the study period (2017-2028). The therapeutic market of GEJ-NET is dominated by Somatostain Analogues (Lanreotide Depot/ Octreotide LAR), Neo-Adjuvant Chemotherapies (cisplatin/etoposide) and Chemo combination regimen (capecitabine and temozolomide). The market size of GEJ-NET first line treatment (which includes Neo-Adjuvant Chemotherapies (cisplatin/etoposide) and Somatostain Analogues (Lanreotide Depot/ Octreotide LAR)) was found to be USD XXX Million in 2017. Moreover, the expected launch of two potential therapies by 2028 may provide better treatment options for GEJ-NET patients.
Gastro-Esophageal Junction Neuroendocrine Tumor (GEJ-NET) - Drugs Uptake
This section focusses on the rate of uptake of the potential drugs recently launched in the market or will get launched in the market during the study period from 2017-2028. The analysis covers market uptake by drugs; patient uptake by therapies and sales of each drug.
This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.
Due to the complexity of the disease, not many companies are targeting this disease. However, a few pharmaceutical giants are developing their therapies for the treatment of Gastroenteropancreatic Neuroendocrine tumor (GEP-NET) which includes foregut (esophagus, stomach, proximal duodenum, liver, and pancreas), midgut and hindgut. The foregut (esophagus and stomach) further forms GEJ-NET. To name a few of these companies: ITM Isotopen Technologien München AG, and EpicentRx.
The dynamics of GEJ-NET market is anticipated to change in the coming years owing to the expected launch of emerging therapies during the forecasted period of 2019-2028. The emerging therapies focused on the treatment of GEJ-NETs include 177Lu-edotreotide PRRT (ITM Isotopen Technologien Muenchen), RRx-001 (EpicentRx).
Gastro-Esophageal Junction Neuroendocrine Tumor (GEJ-NET) Report Insights
• Patient Population
• Therapeutic Approaches
• Pipeline Analysis
• Market Size and Trends
• Market Opportunities
• Impact of upcoming Therapies
Gastro-Esophageal Junction Neuroendocrine Tumor (NET) Report Key Strengths
• 10 Years Forecast
• Epidemiology Segmentation
• Key Cross Competition
• Market Size by Therapies
• Drugs Uptake
Gastro-Esophageal Junction Neuroendocrine Tumor (NET) Report Assessment
• Pipeline Product Profiles
• Key Products and Key Players
• Market Drivers and Barriers
• This DelveInsight report will help to develop Business Strategies by understanding the trends shaping and driving Gastro-Esophageal Junction Neuroendocrine Tumor (GEJ-NET) market
• Organize sales and marketing efforts by identifying the best opportunities for Gastro-Esophageal Junction Neuroendocrine Tumor (GEJ-NET) market
• To understand the future market competition in the Gastro-Esophageal Junction Neuroendocrine Tumor (GEJ-NET) market.